Abstract PD1-04: Results of a phase II double-blinded, randomized, placebo-controlled clinical trial of Indoximod, an Indoleamine-2,3-dioxygenase 1 (IDO1) inhibitor, in combination with Taxane chemotherapy in metastatic breast cancer (MBC)Veronica Mariotti, Hatem Soliman, Patrick M. Dillon et al.|Cancer Research|2020Cited by 2